Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAMP: Selective Treatment for mCRPC Subtypes
NCT03696186Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Aug 2018
- Primary completion
- Aug 2022
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abiraterone, carboplatin, gefitinib, vemurafenib, celecoxib and 4 more in metastatic castration-resistant prostate cancer (mCRPC) (6 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Overall Survival at 40 months. Status: unknown.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03696186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03696186.